Despite the same CCR5 target;...in vitro susceptib
Post# of 145570
Leronlimab may have some Advantages over FDA Approved Miraviroc as a clinically valuable CCR5 antagonist,... including LOWER toxicity,... less Drug-Drug INTERACTION issues and LESS frequent dosing... Leronlimab can play a key role in subjects with VERY limited therapeutic options and CCR5-tropic virus.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)